The New England Journal of Medicine published a clinical trial yesterday showing extremely positive results with the use of CBD, Cannabidiol, to reduce seizures in children suffering from Dravet syndrome.  The study, funded by GW Pharmaceuticals,  involved  120 patients with Dravet syndrome, an epilepsy disorder, ranging in age from nearly 2 to 18 years old, and were randomly assigned to receive either an oral solution of cannabidiol or a placebo for a 14-week period.

Results showed the frequency of convulsive seizures decreased from an average of 12.4 to 5.9 per month in the cannabidiol group, compared with 14.9 to 14.1 in the placebo group. The study was a randomized, double-blind, placebo-controlled human trial, which is the highest standard  of testing for any new medicine.

This clinical trial results may open the door for the Food and Drug Administration and the National Institute of Drug Abuse to petition the DEA to remove cannabis, or parts of cannabis, from under it’s current Schedule 1 classification to allow more medical testing.

For the sake of kids’ suffering, let’s hope so!

About The Author

D. Michael Brooks

Kush Life CEO

I'm a creative entrepreneur and cannabis enthusiast. My goal with this website is first and foremost to have fun! I want to hear and share the stories of other cannabis endeavors and hope to spread positivity and information.

Leave a Reply